相关实验视频
Updated: Jul 18, 2025

09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.5K
长期口服N-棕甲基乙醇胺对轻度认知障碍患者的影响:研究协议
Michela Bossa1, Ornella Argento1, Chiara Piacentini1
1Behavioral Neuropsychology Laboratory, I.R.C.C.S. "Santa Lucia" Foundation, 00179 Rome, Italy.
Brain sciences
|August 26, 2023
概括
在减少神经炎症和神经毒性方面,N-palmitoylethanolamine (PEA) 是有前途的. 这项研究调查了PEA.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- N-棕乙醇胺 (PEA) 具有抗神经炎症,止痛和神经保护性质.
- 在临床前模型中,PEA已经证明在预防粉样β (Aβ) 介导的神经炎症和神经毒性方面具有有效性.
- 现有的人类研究表明PEA的潜在治疗益处.
研究的目的:
- 评估12个月口服N-palmitoylethanolamine (PEA) 给轻度认知障碍 (MCI) 患者的抗神经炎症作用.
- 评估PEA对认知功能和神经炎症和神经元损伤的生物化学标记物的影响.
- 探索PEA治疗,认知变化和炎症标志物之间的相关性.
主要方法:
- 一个为期12个月的随机,安慰剂对照试验,涉及患有MCI的受试者.
- 参与者接受了口服PEA或安慰剂.
- 在治疗开始和治疗后进行了认知评估和血液和尿液的生物化学分析.
主要成果:
- 假设PEA的使用会影响神经心理和行为评估得分.
- 预计血液和尿液中的炎症和神经元损伤标志物的变化.
- 将分析临床评分和生化变化之间的相关性.
结论:
- 这项研究旨在确定PEA是否可以减轻MCI患者的神经炎症和认知衰退.
- 这些发现将阐明PEA作为神经退行性疾病治疗剂的潜力.
- 这项研究可以为PEA在管理轻度认知障碍方面的作用提供证据.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was在MCI中,MCI是MCI.在PEA中,PEA是PEA.认知 认知 认知神经炎症是一种神经炎症.相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213

